Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 11;24(Suppl H):H3-H7.
doi: 10.1093/eurheartjsupp/suac057. eCollection 2022 Nov.

Cardiovascular prevention: sometimes dreams can come true

Roberto Ferrari  1 , Paolo Cimaglia  2 , Claudio Rapezzi  1   2 , Luigi Tavazzi  2 , Gabriele Guardigli  1
Affiliations

Cardiovascular prevention: sometimes dreams can come true

Roberto Ferrari et al. Eur Heart J Suppl. .

Abstract

Cardiovascular disease (CVD) is a chronic condition driven by the complex interaction of different risk factors including genetics, lifestyle, environment, etc. which, differently from other pathologies, can be prevented. Treatment of CVD has been inconceivably successful but now it seems that it has reached a plateau suggesting that prevention is the way forward. However, the COVID-19 pandemic has spotted all the limits of the actual health system regarding territorial and, particularly, of preventive medicine. To this end, recently, the SCORE2 risk prediction algorithms, a contemporary model to estimate 10-years risk of CVD in Europe and the new guidelines on prevention have been released. The present review article describes a dream: how prevention of CVD should be addressed in the future. New concepts and paradigms like early genetically personalized and imaging driven risk factors, cardiac risk cartography, measurements of the exposome, estimation of costs of a delayed outcome vs. healthy lifespan, are all addressed. We highlight the importance of technologies and the concept of being engaged in a 'healthy' and not just 'sick' system as it is today. The concept of 'clearing house' with a 'healthcare team' instead of a 'heart team' is described. Finally, we articulate the four points necessary for the dream to come true.

Keywords: CVD; Health system; Prevention; Risk scores.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: R.F. reports having received research grants and personal fees from Novartis and Servier personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici outside the submitted work. He is a director of Art Research and Science S.r.l (A.R.S.1). P.C. has no conflict of interest to disclose. C.R. reports grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Novartis, personal fees from Alnylam Pharmaceuticals, outside the submitted work. L.T. reports personal fees from SERVIER, personal fees from CVIE THERAPEUTICS outside the submitted work. G.G. has no conflict of interest to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Jr, Virani SS, Williams KA, Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596–e646. - PMC - PubMed
    1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Angelantonio ED, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–3337. - PubMed
    1. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Nicholls SJ, Sabatine MS. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA 2019;322:1381–1391. - PMC - PubMed
    1. Liu G, Shi M, Mosley JD, Weng C, Zhang Y, Lee M, Jarvik GP, Hakonarson H, Namjou-Khales B, Sleiman P, Luo Y, Mentch F, Denny JC, Linton MF, Wei WQ, Stein CM, Feng Q. A Mendelian randomization approach using 3-HMG-coenzyme-A reductase gene variation to evaluate the association of statin-induced low-density lipoprotein cholesterol lowering with noncardiovascular disease phenotypes. JAMA Netw Open 2021;4:e2112820. - PMC - PubMed
    1. Tokgozoglu L, Torp-Pedersen C. Redefining cardiovascular risk prediction: is the crystal ball clearer now? Eur Heart J 2021;42:2468–2471. - PubMed